GSK plc ADR's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters.
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Turnover | $32.7B | $31.4B | $30.3B | $29.3B |
| Cost of sales | ($9.0B) | ($9.0B) | ($8.6B) | ($9.6B) |
| Gross profit | $23.6B | $22.3B | $21.8B | $19.8B |
| Selling, general and administration | ($9.1B) | ($11.0B) | ($9.4B) | ($8.4B) |
| Research and development | ($7.5B) | ($6.4B) | ($6.2B) | ($5.5B) |
| Royalty income | $879.0M | $639.0M | $953.0M | $758.0M |
| Other operating income/(expense) | $16.0M | ($1.5B) | ($363.0M) | ($235.0M) |
| Operating profit | $7.9B | $4.0B | $6.7B | $6.4B |
| Finance income | $169.0M | $122.0M | $115.0M | $76.0M |
| Finance expense | ($701.0M) | ($669.0M) | ($792.0M) | ($879.0M) |
| Share of after tax profit/(loss) of associates and joint ventures | $1.0M | ($3.0M) | ($5.0M) | ($2.0M) |
| Profit/(loss) on disposal of interests in associates and joint ventures | $0 | $6.0M | — | — |
| Profit before taxation | $7.4B | $3.5B | $6.1B | $5.6B |
| Taxation | ($1.1B) | ($526.0M) | ($756.0M) | ($707.0M) |
| Profit after taxation | $6.3B | $3.0B | $5.3B | $15.6B |
| Profit attributable to non-controlling interests | $573.0M | $376.0M | $380.0M | $665.0M |
| Profit attributable to shareholders | $5.7B | $2.6B | $4.9B | $15.0B |
| Basic earnings per share (pence) (in pence per share) | $1.41 | $0.63 | $1.22 | $3.71 |
| Diluted earnings per share (pence) (in pence per share) | $1.39 | $0.62 | $1.20 | $3.66 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Property, plant and equipment | $9.3B | $9.2B | $9.0B | $8.9B |
| Right of use assets | $726.0M | $846.0M | $937.0M | $687.0M |
| Goodwill | $7.0B | $7.0B | $6.8B | $7.0B |
| Other intangible assets | $16.7B | $15.5B | $14.8B | $14.3B |
| Investments in associates and joint ventures | $89.0M | $96.0M | $55.0M | $74.0M |
| Other investments | $1.0B | $1.1B | $1.1B | $1.5B |
| Deferred tax assets | $6.5B | $6.8B | $6.0B | $5.7B |
| Derivative financial instruments | $0 | $1.0M | — | $0 |
| Other non-current assets | $2.1B | $1.9B | $1.6B | $1.2B |
| Total non-current assets | $43.6B | $42.5B | $40.4B | $39.4B |
| Inventories | $5.9B | $5.7B | $5.5B | $5.1B |
| Current tax recoverable | $288.0M | $489.0M | $373.0M | $405.0M |
| Trade and other receivables | $7.5B | $6.8B | $7.4B | $7.1B |
| Derivative financial instruments | $121.0M | $109.0M | $130.0M | $190.0M |
| Liquid investments | $9.0M | $21.0M | $42.0M | $67.0M |
| Cash and cash equivalents | $3.4B | $3.9B | $2.9B | $3.7B |
| Assets held for sale | $300.0M | $3.0M | $76.0M | $98.0M |
| Total current assets | $17.5B | $17.0B | $18.6B | $20.8B |
| Total assets | $61.1B | $59.5B | $59.0B | $60.1B |
| Short-term borrowings | ($3.0B) | ($2.3B) | ($2.8B) | ($4.0B) |
| Contingent consideration liabilities | ($1.3B) | ($1.2B) | ($1.1B) | ($1.3B) |
| Trade and other payables | ($15.4B) | ($15.3B) | ($15.8B) | ($16.3B) |
| Derivative financial instruments | ($75.0M) | ($192.0M) | ($114.0M) | ($183.0M) |
| Current tax payable | ($498.0M) | ($703.0M) | ($500.0M) | ($471.0M) |
| Short-term provisions | ($938.0M) | ($1.9B) | ($744.0M) | ($652.0M) |
| Liabilities relating to assets held for sale | ($139.0M) | — | — | — |
| Total current liabilities | ($21.4B) | ($21.7B) | ($21.1B) | ($22.8B) |
| Long-term borrowings | ($14.7B) | ($14.6B) | ($15.2B) | ($17.0B) |
| Deferred tax liabilities | ($291.0M) | ($382.0M) | ($311.0M) | ($289.0M) |
| Pensions and other post-employment benefits | ($1.7B) | ($1.9B) | ($2.3B) | ($2.6B) |
| Derivative financial instruments | ($67.0M) | — | — | $0 |
| Other provisions | ($610.0M) | ($589.0M) | ($495.0M) | ($532.0M) |
| Contingent consideration liabilities | ($5.4B) | ($6.1B) | ($5.6B) | ($5.8B) |
| Other non-current liabilities | ($1.0B) | ($1.1B) | ($1.1B) | ($899.0M) |
| Total non-current liabilities | ($23.8B) | ($24.7B) | ($25.1B) | ($27.2B) |
| Total liabilities | ($45.2B) | ($46.4B) | ($46.2B) | ($50.0B) |
| Net assets | $16.0B | $13.1B | $12.8B | $10.1B |
| Share capital | $1.3B | $1.3B | $1.3B | $1.3B |
| Share premium | $3.5B | $3.5B | $3.5B | $3.4B |
| Retained earnings | $10.2B | $7.8B | $7.2B | $4.4B |
| Other reserves | $1.3B | $1.1B | $1.3B | $1.4B |
| Shareholders’ equity | $16.4B | $13.7B | $13.3B | $10.6B |
| Non-controlling interests | ($421.0M) | ($585.0M) | ($552.0M) | ($502.0M) |
| Total equity | $16.0B | $13.1B | $12.8B | $10.1B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Total profit for the year | $6.3B | — | — | — |
| Adjustments reconciling profit after tax to operating cash flows | $2.7B | $4.9B | $2.8B | — |
| Cash generated from operations | $8.9B | $7.9B | — | — |
| Taxation paid | ($1.2B) | ($1.3B) | ($1.3B) | — |
| Total net cash inflow/(outflow) from operating activities | $7.7B | $6.6B | $6.8B | — |
| Purchase of property, plant and equipment | ($1.3B) | ($1.4B) | ($1.3B) | — |
| Proceeds from sale of property, plant and equipment | $24.0M | $65.0M | $28.0M | — |
| Purchase of intangible assets | ($1.6B) | ($1.6B) | ($1.0B) | — |
| Proceeds from sale of intangible assets | $115.0M | $131.0M | $12.0M | — |
| Purchase of equity investments | ($92.0M) | ($103.0M) | ($123.0M) | — |
| Proceeds from sale of equity investments | $189.0M | $2.4B | $1.8B | — |
| Share transactions with non-controlling interests | $0 | ($1.0M) | — | — |
| Purchase of businesses, net of cash acquired | ($1.7B) | ($805.0M) | ($1.5B) | — |
| Investments in associates and joint ventures | $0 | ($43.0M) | $0 | — |
| Proceeds from disposal of associates and joint ventures | $0 | $0 | $1.0M | — |
| Contingent consideration paid | ($17.0M) | ($19.0M) | ($11.0M) | — |
| Disposal of businesses | ($27.0M) | ($18.0M) | $49.0M | — |
| Interest received | $154.0M | $138.0M | $115.0M | — |
| (Increase)/decrease in liquid investments | $11.0M | $21.0M | $72.0M | — |
| Dividends from joint ventures and associates | $67.0M | $15.0M | $11.0M | — |
| Dividend and distributions from investments | $20.0M | $16.0M | $220.0M | — |
| Total net cash inflow/(outflow) from investing activities | ($4.2B) | ($1.2B) | ($1.6B) | — |
| Issue of share capital | 15.0M | 20.0M | 10.0M | — |
| Repayment of long-term loans | ($1.4B) | ($1.6B) | ($144.0M) | — |
| Issue of long-term notes | $2.0B | $1.1B | $223.0M | — |
| Net increase/(decrease) in short-term loans | $1.1B | ($811.0M) | — | — |
| Increase in other short-term loans | $130.0M | $266.0M | — | — |
| Repayment of other short-term loans | ($288.0M) | ($81.0M) | — | — |
| Repayment of lease liabilities | ($241.0M) | ($226.0M) | ($197.0M) | — |
| Interest paid | ($679.0M) | ($632.0M) | ($766.0M) | — |
| Dividends paid to shareholders | ($2.6B) | ($2.4B) | ($2.2B) | — |
| Purchase of treasury shares | -1.4B | — | — | — |
| Distribution to non-controlling interests | ($391.0M) | ($416.0M) | — | — |
| Contributions from non-controlling interests | $0 | $9.0M | $7.0M | — |
| Other financing items | $46.0M | $129.0M | $334.0M | — |
| Total net cash inflow/(outflow) from financing activities | ($3.7B) | ($4.7B) | ($5.6B) | — |
| Increase/(decrease) in cash and bank overdrafts in the year | ($177.0M) | $599.0M | ($468.0M) | — |
| Cash and bank overdrafts at the beginning of the year | $3.4B | $2.9B | $3.4B | — |
| Exchange adjustments | ($19.0M) | ($54.0M) | ($99.0M) | — |
| Cash and bank overdrafts at the end of the year | $3.2B | — | — | — |
| Cash and cash equivalents | $3.4B | $3.9B | $2.9B | $3.7B |
| Bank overdrafts | ($190.0M) | ($467.0M) | ($78.0M) | ($298.0M) |
| Cash and bank overdrafts | $3.2B | $3.4B | — | — |
GSK plc ADR score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.